Volpara reaches milestone in tech-driven cancer fight
Volpara reaches milestone in tech-driven fight against breast cancer
Microsoft Co-Sell Partner Volpara signs with Mercy Radiology and BreastScreen Central
New Zealand, 12 November 2018 – Some of the greatest advances in the fight against breast cancer are happening not in the lab but in a Kiwi software company. Wellington-based Volpara® Solutions™ is helping save lives around the globe with its revolutionary AI technologies that are optimising breast screening to catch breast cancers earlier and reduce costs. In New Zealand, it has recently begun supporting Auckland-based Mercy Radiology and in October signed a contract with its first public sector client, BreastScreen Central (Lower Hutt). With assistance from Microsoft, it’s now aiming to further global understanding of breast cancer and its detection.
It can be difficult to isolate cancers in breast tissue that is particularly ‘dense’, as both appear white on X-rays. To aid in the detection of breast cancer at an earlier stage, the Volpara®Enterprise™ software, built on Microsoft Azure, uses artificial intelligence to automatically and objectively assess a women’s breast density. Using this information, Volpara’s customers can identify patients with dense breasts that may benefit from supplemental imaging such as ultrasound. The outcome is identifying and treating the disease in its earliest stages, reducing the incidence of “interval cancers” (cancers that arise between breast screens), and lower treatment costs.
“Before, we were subjectively assessing breast density, but now we have an objective risk-assessment to help us identify those patients that need additional methods of screening to mammography, in order to increase detection of breast cancer,” said Dr Sugania Reddy, radiologist at Auckland’s Mercy Radiology. “In patients with high breast density, the mammogram sensitivity is reduced for detection of breast cancer. Using Volpara software we recognise the need immediately for supplementary screening of these patients and therefore increase our ability the find these cancers at an earlier stage, resulting in an overall better prognosis.”
Volpara’s analytics software also uses Microsoft Power BI to analyse the quality of every mammogram. Having access to this analysis helps radiographers understand areas where they can refine their techniques to produce better mammograms. The software monitors more than 100 performance metrics to guide radiographers on enhancing their positioning skills, making examinations more comfortable and capturing higher-quality images. This simultaneously provides quality control for breast screens and helps decrease costs by reducing the need for technical recalls.
Volpara Chief Executive Dr Ralph Highnam was inspired to pursue a career in breast imaging technology after discussing his career with a former lecturer at Oxford University. He was looking for a path to explore his interest in AI, and his professor encouraged him to consider finding a way to improve breast screening standards, having just lost his mother-in-law to breast cancer. The result was Volpara, now an ASX-listed business whose solutions are used in private hospitals around the world, from the US to Japan, Australia and New Zealand.
Microsoft has also facilitated a trial with healthcare providers in Singapore through its Co-Sell programme. As a Microsoft Co-Sell Partner, Volpara is able to access marketing and communications support, technical assistance and the services of a specialist Business Development Manager to help it use Microsoft’s global networks to expand into other markets and business areas.
“While everything our partners do has the potential to make people’s lives better, it’s not often you get the opportunity to work with a business that is literally saving lives the way Volpara does,” said Ryan Tarak, Partner Development Manager for Microsoft New Zealand. “We’re really excited to be helping Volpara assist countless more breast cancer patients worldwide, especially as it moves into the next phase of the fight against breast cancer, using data-driven research.”
Dr Highnam said computer-aided detection is the next challenge for breast screening software developers. “It’s still early days, but this is the next major frontier in combating breast cancer, which we hope will help reduce both global radiologist shortages and waiting lists. Breast cancer affects not only millions of women worldwide but also their families, friends and colleagues, and we look forward to finding more ways to optimise early detection and treatment.”
More details on Microsoft’s Co-Sell programme are available here.
About Volpara Health Technologies Limited
Volpara (ASX “VHT” @volparadensity) provides digital health solutions for the early detection of breast cancer based on automated, objective measurements of breast density and quality. Its mission is to reduce the mortality and cost of breast cancer by providing clinically validated software that supports personalised, high-quality breast cancer screening. For more information, visit www.volparasolutions.com.
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.